share_log

中國生物製藥：自願公告 - 與勃林格殷格翰就腫瘤創新產品組合在中國建立戰略合作夥伴關係

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA

香港交易所 ·  Apr 7 19:59
Summary by Moomoo AI
中國生物製藥有限公司（簡稱「中生製藥」）宣布已與勃林格殷格翰建立戰略合作夥伴關係，共同開發和商業化勃林格殷格翰在中國大陸的腫瘤管線。合作包括多個處於臨床階段的資產，如brigimadlin、zongertinib和BI 764532等，旨在滿足中國市場尚未被滿足的臨床需求。此次合作將有助於豐富中生製藥的腫瘤產品組合，並將產品收入計入公司的合併財務報表。該協議標誌著雙方在腫瘤領域的合作開始，並有助於中生製藥擴大國際視野，成為跨國公司的首選合作夥伴。董事會於2024年4月8日宣布此消息。
中國生物製藥有限公司（簡稱「中生製藥」）宣布已與勃林格殷格翰建立戰略合作夥伴關係，共同開發和商業化勃林格殷格翰在中國大陸的腫瘤管線。合作包括多個處於臨床階段的資產，如brigimadlin、zongertinib和BI 764532等，旨在滿足中國市場尚未被滿足的臨床需求。此次合作將有助於豐富中生製藥的腫瘤產品組合，並將產品收入計入公司的合併財務報表。該協議標誌著雙方在腫瘤領域的合作開始，並有助於中生製藥擴大國際視野，成為跨國公司的首選合作夥伴。董事會於2024年4月8日宣布此消息。
CHINA BIOPHARMACEUTICAL CO., LTD. (HEREINAFTER REFERRED TO AS “CHINESE PHARMACEUTICALS”) ANNOUNCED THAT IT HAS ESTABLISHED A STRATEGIC PARTNERSHIP WITH BORINGYINGHAN TO JOINTLY DEVELOP AND COMMERCIALIZE BURNINGYGHAN'S ONCOLOGY PIPELINE IN MAINLAND CHINA. The collaboration includes several clinical-stage assets, such as brigimadlin, zongertinib, and BI 764532, and others, aimed at meeting the unmet clinical needs of the Chinese market. This collaboration will help enrich the oncology product portfolio of CUHK Pharmaceuticals and incorporate product revenues into the company's consolidated financial statements. The agreement marks the beginning of cooperation between the two sides in the field of oncology and helps SSE Pharma expand its international reach and become the preferred partner for multinational companies. The Board of Directors announced this announcement on 8 April 2024.
CHINA BIOPHARMACEUTICAL CO., LTD. (HEREINAFTER REFERRED TO AS “CHINESE PHARMACEUTICALS”) ANNOUNCED THAT IT HAS ESTABLISHED A STRATEGIC PARTNERSHIP WITH BORINGYINGHAN TO JOINTLY DEVELOP AND COMMERCIALIZE BURNINGYGHAN'S ONCOLOGY PIPELINE IN MAINLAND CHINA. The collaboration includes several clinical-stage assets, such as brigimadlin, zongertinib, and BI 764532, and others, aimed at meeting the unmet clinical needs of the Chinese market. This collaboration will help enrich the oncology product portfolio of CUHK Pharmaceuticals and incorporate product revenues into the company's consolidated financial statements. The agreement marks the beginning of cooperation between the two sides in the field of oncology and helps SSE Pharma expand its international reach and become the preferred partner for multinational companies. The Board of Directors announced this announcement on 8 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more